GlassScriptPhysician profile
Christopher Ryan Vela
NPI 1366728909
$10,160.87
in general payments reported to CMS, 2019-2025
40 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,977 · 2022: $1,899 · 2023: $1,848 · 2024: $1,472 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,379 · Travel and Lodging: $810 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,379.38 |
| Travel and Lodging | $810.24 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,782.28 | 2021-2025 | Farxiga, Wainua, Tezspire |
| Cvrx, INC. | $1,279.97 | 2025 | Barostim Neo System |
| Amgen INC. | $1,142.89 | 2021-2025 | Repatha, Repatha, Tezspire |
| Pfizer INC. | $712.23 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $504.61 | 2021-2023 | Cuvitru |
| Glaxosmithkline, LLC. | $500.27 | 2021-2023 | Trelegy Ellipta, Nucala, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.47 | 2021-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $445.17 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Amarin Pharma, INC. | $401.60 | 2021 | |
| Csl Behring | $271.66 | 2021-2023 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $249.98 | 2021-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $242.94 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.56 | 2021-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $209.27 | 2024-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $206.97 | 2021-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $179.05 | 2021-2023 | Yupelri |
| Grifols USA, LLC | $170.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $156.82 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $132.14 | 2024-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $129.65 | 2021 | |
| Genzyme Corporation | $128.67 | 2021-2023 | |
| Leo Pharma INC. | $86.26 | 2023 | Adbry |
| Genentech USA, INC. | $73.91 | 2022-2023 | Xolair |
| Medtronic, INC. | $55.65 | 2025 | Corevalve Evolut R |
| Kaleo, INC. | $48.78 | 2021-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $47.96 | 2022-2023 | Ruconest |
| Tactile Systems Technology INC | $42.85 | 2021 | |
| Lilly USA, LLC | $37.88 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $27.16 | 2022 | |
| Alk-Abello, INC | $27.10 | 2023 | Alternaria Tenuis, Pre-Pen, Timothy, Standardized |
| Boston Scientific Corporation | $25.71 | 2025 | Watchman Flx |
| Kiniksa Pharmaceuticals, LTD. | $23.47 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $20.40 | 2021 | |
| Blueprint Medicines Corporation | $19.81 | 2023 | |
| Optinose US, INC. | $18.58 | 2021 | |
| Esperion Therapeutics, INC. | $16.72 | 2021 | |
| Lundbeck LLC | $16.24 | 2021 | |
| Daiichi Sankyo INC. | $15.40 | 2024 | Injectafer |
| Scpharmaceuticals INC. | $14.89 | 2025 | |
| Philips North America LLC | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.